Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Non-Current Assets (2020 - 2022)

Atea Pharmaceuticals has reported Non-Current Assets over the past 3 years, most recently at $4.6 million for Q3 2022.

  • Quarterly results put Non-Current Assets at $4.6 million for Q3 2022, up 731.72% from a year ago — trailing twelve months through Sep 2022 was $14.0 million (up 746.91% YoY), and the annual figure for FY2021 was $489000.0, up 215.48%.
  • Non-Current Assets for Q3 2022 was $4.6 million at Atea Pharmaceuticals, down from $4.9 million in the prior quarter.
  • Over the last five years, Non-Current Assets for AVIR hit a ceiling of $4.9 million in Q2 2022 and a floor of $155000.0 in Q4 2020.
  • Median Non-Current Assets over the past 3 years was $558000.0 (2021), compared with a mean of $1.9 million.
  • Biggest five-year swings in Non-Current Assets: tumbled 67.04% in 2021 and later skyrocketed 1028.64% in 2022.
  • Atea Pharmaceuticals' Non-Current Assets stood at $155000.0 in 2020, then surged by 215.48% to $489000.0 in 2021, then skyrocketed by 849.08% to $4.6 million in 2022.
  • The last three reported values for Non-Current Assets were $4.6 million (Q3 2022), $4.9 million (Q2 2022), and $4.0 million (Q1 2022) per Business Quant data.